Cargando…

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin

Empagliflozin (EMPA) is a sodium–glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases. However, the possible benefits and mechanisms of its antiarrhythmic effects in cardiac ti...

Descripción completa

Detalles Bibliográficos
Autores principales: Jhuo, Shih-Jie, Liu, I-Hsin, Tasi, Wei-Chung, Chou, Te-Wu, Lin, Yi-Hsiung, Wu, Bin-Nan, Lee, Kun-Tai, Lai, Wen-Ter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200966/
https://www.ncbi.nlm.nih.gov/pubmed/34198942
http://dx.doi.org/10.3390/ijms22116105
_version_ 1783707706257833984
author Jhuo, Shih-Jie
Liu, I-Hsin
Tasi, Wei-Chung
Chou, Te-Wu
Lin, Yi-Hsiung
Wu, Bin-Nan
Lee, Kun-Tai
Lai, Wen-Ter
author_facet Jhuo, Shih-Jie
Liu, I-Hsin
Tasi, Wei-Chung
Chou, Te-Wu
Lin, Yi-Hsiung
Wu, Bin-Nan
Lee, Kun-Tai
Lai, Wen-Ter
author_sort Jhuo, Shih-Jie
collection PubMed
description Empagliflozin (EMPA) is a sodium–glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases. However, the possible benefits and mechanisms of its antiarrhythmic effects in cardiac tissue have not yet been reported. In this study, we elucidated the possible antiarrhythmic effects and mechanisms of EMPA treatment in cardiac tissues of metabolic syndrome (MS) mice. A total of 20 C57BL/6J mice (age: 8 weeks) were divided into four groups: (1) control group, mice fed a standard chow for 16 weeks; (2) MS group, mice fed a high-fat diet for 16 weeks; (3) EMPA group, mice fed a high-fat diet for 12 weeks and administered EMPA at 10 mg/kg daily for the following 4 weeks; and (4) glibenclamide (GLI) group, mice fed a high-fat diet for 12 weeks and administered GLI at 0.6 mg/kg daily for the following 4 weeks. All mice were sacrificed after 16 weeks of feeding. The parameters of electrocardiography (ECG), echocardiography, and the effective refractory period (ERP) of the left ventricle were recorded. The histological characteristics of cardiac tissue, including connexin (Cx) expression and fibrotic areas, were also evaluated. Compared with the MS group, the ECG QT interval in the EMPA group was significantly shorter (57.06 ± 3.43 ms vs. 50.00 ± 2.62 ms, p = 0.011). The ERP of the left ventricle was also significantly shorter in the EMPA group than that in the GLI group (20.00 ± 10.00 ms vs. 60.00 ± 10.00 ms, p = 0.001). The expression of Cx40 and Cx43 in ventricular tissue was significantly lower in the MS group than in the control group. However, the downregulation of Cx40 and Cx43 was significantly attenuated in the EMPA group compared with the MS and GLI groups. The fibrotic areas of ventricular tissue were also fewer in the EMPA group than that in the MS group. In this study, the ECG QT interval in the EMPA group was shorter than that in the MS group. Compared with the MS group, the EMPA group exhibited significant attenuation of downregulated connexin expression and significantly fewer fibrotic areas in ventricles. These results may provide evidence of possible antiarrhythmic effects of EMPA.
format Online
Article
Text
id pubmed-8200966
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82009662021-06-15 Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin Jhuo, Shih-Jie Liu, I-Hsin Tasi, Wei-Chung Chou, Te-Wu Lin, Yi-Hsiung Wu, Bin-Nan Lee, Kun-Tai Lai, Wen-Ter Int J Mol Sci Article Empagliflozin (EMPA) is a sodium–glucose transporter 2 (SGLT2) inhibitor that functions as a new-generation glucose-lowering agent and has been proven to be beneficial for patients with cardiovascular diseases. However, the possible benefits and mechanisms of its antiarrhythmic effects in cardiac tissue have not yet been reported. In this study, we elucidated the possible antiarrhythmic effects and mechanisms of EMPA treatment in cardiac tissues of metabolic syndrome (MS) mice. A total of 20 C57BL/6J mice (age: 8 weeks) were divided into four groups: (1) control group, mice fed a standard chow for 16 weeks; (2) MS group, mice fed a high-fat diet for 16 weeks; (3) EMPA group, mice fed a high-fat diet for 12 weeks and administered EMPA at 10 mg/kg daily for the following 4 weeks; and (4) glibenclamide (GLI) group, mice fed a high-fat diet for 12 weeks and administered GLI at 0.6 mg/kg daily for the following 4 weeks. All mice were sacrificed after 16 weeks of feeding. The parameters of electrocardiography (ECG), echocardiography, and the effective refractory period (ERP) of the left ventricle were recorded. The histological characteristics of cardiac tissue, including connexin (Cx) expression and fibrotic areas, were also evaluated. Compared with the MS group, the ECG QT interval in the EMPA group was significantly shorter (57.06 ± 3.43 ms vs. 50.00 ± 2.62 ms, p = 0.011). The ERP of the left ventricle was also significantly shorter in the EMPA group than that in the GLI group (20.00 ± 10.00 ms vs. 60.00 ± 10.00 ms, p = 0.001). The expression of Cx40 and Cx43 in ventricular tissue was significantly lower in the MS group than in the control group. However, the downregulation of Cx40 and Cx43 was significantly attenuated in the EMPA group compared with the MS and GLI groups. The fibrotic areas of ventricular tissue were also fewer in the EMPA group than that in the MS group. In this study, the ECG QT interval in the EMPA group was shorter than that in the MS group. Compared with the MS group, the EMPA group exhibited significant attenuation of downregulated connexin expression and significantly fewer fibrotic areas in ventricles. These results may provide evidence of possible antiarrhythmic effects of EMPA. MDPI 2021-06-05 /pmc/articles/PMC8200966/ /pubmed/34198942 http://dx.doi.org/10.3390/ijms22116105 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jhuo, Shih-Jie
Liu, I-Hsin
Tasi, Wei-Chung
Chou, Te-Wu
Lin, Yi-Hsiung
Wu, Bin-Nan
Lee, Kun-Tai
Lai, Wen-Ter
Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
title Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
title_full Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
title_fullStr Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
title_full_unstemmed Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
title_short Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
title_sort characteristics of ventricular electrophysiological substrates in metabolic mice treated with empagliflozin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200966/
https://www.ncbi.nlm.nih.gov/pubmed/34198942
http://dx.doi.org/10.3390/ijms22116105
work_keys_str_mv AT jhuoshihjie characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT liuihsin characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT tasiweichung characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT choutewu characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT linyihsiung characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT wubinnan characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT leekuntai characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin
AT laiwenter characteristicsofventricularelectrophysiologicalsubstratesinmetabolicmicetreatedwithempagliflozin